<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Humana Press</PublisherName>
    <PublisherLocation>Totowa, NJ</PublisherLocation>
  </PublisherInfo>
  <Series>
    <SeriesInfo SeriesType="Series" TocLevels="0">
      <SeriesID>7651</SeriesID>
      <SeriesPrintISSN>1064-3745</SeriesPrintISSN>
      <SeriesElectronicISSN>1940-6029</SeriesElectronicISSN>
      <SeriesTitle Language="En">Methods in Molecular Biology™</SeriesTitle>
    </SeriesInfo>
    <SeriesHeader>
      <EditorGroup>
        <Editor AffiliationIDS="Aff1">
          <EditorName DisplayOrder="Western">
            <GivenName>J.M.</GivenName>
            <FamilyName>Walker</FamilyName>
          </EditorName>
        </Editor>
        <Affiliation ID="Aff1">
          <OrgName>School of Life Sciences University of Hertfordshire</OrgName>
          <OrgAddress>
            <City>Hatfield</City>
            <State>Hertfordshire, AL10 9AB</State>
            <Country>UK</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </SeriesHeader>
    <Book Language="En">
      <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterContentSeparately" OutputMedium="Online" TocLevels="0">
        <BookID>978-1-60327-527-9</BookID>
        <BookTitle>T Cell Protocols</BookTitle>
        <BookSubTitle>Second Edition</BookSubTitle>
        <BookVolumeNumber>514</BookVolumeNumber>
        <BookSequenceNumber>514</BookSequenceNumber>
        <BookDOI>10.1007/978-1-60327-527-9</BookDOI>
        <BookTitleID>145011</BookTitleID>
        <BookPrintISBN>978-1-58829-587-3</BookPrintISBN>
        <BookElectronicISBN>978-1-60327-527-9</BookElectronicISBN>
        <BookChapterCount>11</BookChapterCount>
        <BookCopyright>
          <CopyrightHolderName>Humana Press</CopyrightHolderName>
          <CopyrightYear>2009</CopyrightYear>
        </BookCopyright>
        <BookSubjectGroup>
          <BookSubject Code="SCL" Type="Primary">Life Sciences</BookSubject>
          <BookSubject Code="SCL14005" Priority="1" Type="Secondary">Biochemistry, general</BookSubject>
          <BookSubject Code="SCB14000" Priority="2" Type="Secondary">Immunology</BookSubject>
          <BookSubject Code="SCL16020" Priority="3" Type="Secondary">Cell Culture</BookSubject>
          <SubjectCollection Code="SUCO11642">Biomedical and Life Sciences</SubjectCollection>
        </BookSubjectGroup>
        <BookContext>
          <SeriesID>7651</SeriesID>
        </BookContext>
      </BookInfo>
      <BookHeader>
        <EditorGroup>
          <Editor AffiliationIDS="Aff2">
            <EditorName DisplayOrder="Western">
              <GivenName>Gennaro</GivenName>
              <Particle>De</Particle>
              <FamilyName>Libero</FamilyName>
            </EditorName>
            <Role>Dr</Role>
            <Contact>
              <Email>Gennaro.DeLibero@unibas.ch</Email>
            </Contact>
          </Editor>
          <Affiliation ID="Aff2">
            <OrgName>University of Basel</OrgName>
            <OrgAddress>
              <State>Basel</State>
              <Country>Switzerland</Country>
            </OrgAddress>
          </Affiliation>
        </EditorGroup>
      </BookHeader>
      <Chapter ID="Chap1" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterContentSeparately" OutputMedium="Online" TocLevels="0">
          <ChapterID>1</ChapterID>
          <ChapterNumber>Chapter 1</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-527-9_1</ChapterDOI>
          <ChapterSequenceNumber>1</ChapterSequenceNumber>
          <ChapterTitle Language="En">Analysis of Frequency and Phenotype of Antigen-Specific T Cells</ChapterTitle>
          <ChapterFirstPage>1</ChapterFirstPage>
          <ChapterLastPage>14</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Humana Press, a part of Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2009</CopyrightYear>
          </ChapterCopyright>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <SeriesID>7651</SeriesID>
            <BookID>978-1-60327-527-9</BookID>
            <BookTitle>T Cell Protocols</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author AffiliationIDS="Aff3" CorrespondingAffiliationID="Aff3">
              <AuthorName DisplayOrder="Western">
                <GivenName>Angus</GivenName>
                <FamilyName>Stock</FamilyName>
              </AuthorName>
            </Author>
            <Author AffiliationIDS="Aff3">
              <AuthorName DisplayOrder="Western">
                <GivenName>Vincenzo</GivenName>
                <FamilyName>Cerundolo</FamilyName>
              </AuthorName>
            </Author>
            <Affiliation ID="Aff3">
              <OrgDivision>Nuffield Department of Clinical Medicine</OrgDivision>
              <OrgName>Weatherall Institute of Molecular Medicine</OrgName>
              <OrgAddress>
                <State>Oxford</State>
                <Country>UK</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1" Language="En">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">Over the last decade, our understanding of the cellular immune system has been greatly advanced through the development of methods to identify antigen-specific T cells directly ex vivo. The major reagents and techniques used for this purpose are (i) tetramerised MHC:peptide complexes (tetramers) which bind to specific T-cell receptors (TCR) and (ii) assays that detect T cells which synthesise cytokines in response to cognate stimulation (intracellular cytokine staining (ICS)). Here, we provide a detailed description of the procedure for generating and using class I MHC:peptide tetramers to label peptide-specific T cells and for carrying out ICS to measure antigen-specific T lymphocytes.</Para>
          </Abstract>
          <KeywordGroup Language="En">
            <Heading>Key words</Heading>
            <Keyword>Tetramers</Keyword>
            <Keyword>antigen-specific T cells</Keyword>
            <Keyword>MHC class I</Keyword>
            <Keyword>intracellular cytokine staining</Keyword>
            <Keyword>CTL</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1" OutputMedium="Online" Type="Introduction">
            <Heading>Introduction</Heading>
            <Para TextBreak="No">Accurate measurements of MHC class I restricted T cells have been hampered by the lack of staining reagents capable of identifying antigen-specific cytotoxic T lymphocytes (CTL). Until a few years ago, assays used to detect CTL depended on in vitro culture of antigen-specific CTL and relied on the ability of expanded CTL either to kill target cells or to secrete relatively large amounts of lymphokines. Limiting dilution assay (LDA) was used to quantify CTL precursor frequency and Cr<Superscript>51</Superscript> release assay was used to assess CTL specificity. Both assays were unable to detect cells incapable to proliferate or to show cytotoxic effector function. New methods for detection of antigen-specific CTL have recently been developed (i.e. ELISPOT and intracellular cytokine staining (ICS)) and have allowed to measure in ex vivo assays the frequency of cytokine-secreting effector cells <CitationRef CitationID="CR1">(1</CitationRef>–<CitationRef CitationID="CR4">4)</CitationRef>. Although these assays can reliably measure the frequency of specific CTL able to secrete cytokines, they fail to detect resting or naïve CTL, unable to secrete lymphokines in ex vivo assays. Over the last few years, a novel method has been developed based on the generation of fluorogenic tetrameric HLA class I molecules loaded with defined peptide epitopes, which is independent of the ability of cells to proliferate and secrete lymphokines <CitationRef CitationID="CR5">(5)</CitationRef>. The use of HLA class I tetramers has allowed the characterisation and monitoring of specific viral and tumour responses and has provided an opportunity to greatly accelerate the development of new vaccination strategies (reviewed in <CitationRef CitationID="CR6">(6)</CitationRef>). Here we will describe Materials and Methods to engineer MHC class I tetramers and to carry out combined MHC class I tetramer and ICS of antigen-specific T lymphocytes.</Para>
          </Section1>
          <Section1 ID="Sec2" OutputMedium="Online">
            <Heading>Materials</Heading>
            <Section2 ID="Sec3" OutputMedium="Online">
              <Heading>MHC Class I:Peptide Tetramers</Heading>
              <Para TextBreak="No">
                <OrderedList>
                  <ListItem>
                    <ItemNumber>1.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">pET expression systems (Novagen)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>2.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Oligonucleotide primers, DNA polymerase, ligase and restriction enzymes</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>3.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Agarose and DNA-sequencing systems</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>4.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Ampicillin (used at 100 μg/ml unless otherwise stated)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>5.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">IPTG</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>6.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Triton wash: 50 mM Tris–HCl (pH 8.0), 100 mM NaCl, 0.5% Triton, 10 mM DTT, 1 mM EDTA and 0.1% azide</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>7.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Re-suspension buffer: 50 mM Tris–HCl (pH 8.0), 100 mM NaCl, 10 mM DTT and 1 mM EDTA</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>8.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Urea solution: 8 M urea, 10 mM Tris–HCl (pH 8.0), 100 mM NaH<Subscript>2</Subscript>PO<Subscript>4</Subscript>, 0.1 mM EDTA and 10 mM DTT</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>9.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">BCA protein assay kit</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>10.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Reagents and instruments for SDS gel</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>11.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">0.45 μM filter membrane</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>12.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Refolding buffer: 100 mM Tris–HCl (pH 8.0), 400 mM l-arginine hydrochloride, 2 mM EDTA, 5 mM reduced glutathione, 0.5 mM oxidised glutathione and 0.1 mM PMSF (diluted in H<Subscript>2</Subscript>O)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>13.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Minimal peptide</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>14.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Amicon stir cell (Diaflo PM10 150 mm membrane)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>15.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">FPLC</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>16.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Tris-buffered saline</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>17.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">MgCl<Subscript>2</Subscript>(stock solution, 50 mM)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>18.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Leupeptin (stock solution, 10 μM)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>19.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Pepstatin (stock solution, 10 μM)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>20.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">d-Biotin (stock solution, 4 mM)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>21.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">ATP (stock solution, 50 μM)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>22.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">TBS</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>23.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Bir A Enzyme (stock solution, 500 μM)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>24.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Phycoerythrin-conjugated streptavidin</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>25.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">ELISA reagents</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>26.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Streptavidin-peroxidase</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>27.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">FACS buffer: PBS containing 1% BSA and 0.02% sodium azide</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>28.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Antibodies against T-cell co-receptors (CD8 and CD4)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>29.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Propidium iodide</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>30.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Formaldehyde</Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
              </Para>
            </Section2>
            <Section2 ID="Sec4" OutputMedium="Online">
              <Heading>Intracellular Cytokine Staining</Heading>
              <Para TextBreak="No">
                <OrderedList>
                  <ListItem>
                    <ItemNumber>1.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Synthetic peptides</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>2.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Brefaldin A (diluted in methanol)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>3.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Antibodies against surface antigens (e.g. CD8, CD4, etc.) and intracellular cytokines (e.g. IFN-γ, IL-2, TNF-α, IL-4, IL-10, etc.)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>4.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Formaldehyde: 1% diluted in PBS with 0.1% sodium azide</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>5.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Saponin</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>6.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">T-cell medium: RPMI 1640 supplemented with 10% heat-inactivated foetal calf serum and 5% supplementum complementum (SC: HEPES 23.83 g/l, benzylpenicillin 2×10<Superscript>6</Superscript>U/l, streptomycin 2 g/l, 1-glutamine 6 g/l for RPMI, 50 μM 2-β mercaptoethanol)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>7.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">FACS buffer: PBS containing 1% BSA and 0.02% sodium azide.</Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
              </Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec5" OutputMedium="Online">
            <Heading>Methods</Heading>
            <Para TextBreak="No">Here we shall provide protocols for the two most commonly used flow cytometry-based techniques for enumerating antigen-specific T cells: (1) MHC tetramer analysis and (2) ICS. We shall describe the procedure for generating of class I MHC:peptide tetramers (<Emphasis Type="Bold">Section</Emphasis>
              <InternalRef RefID="Sec6">
                <Emphasis Type="Bold">3.1</Emphasis>
              </InternalRef>) and using these reagents to stain population of cells for identifying antigen-specific T cells (<Emphasis Type="Bold">Section 3.2</Emphasis>). Finally, the protocol for using ICS to identify both peptide- and virus-specific T cells will be described (<Emphasis Type="Bold">Section 3.3</Emphasis>).</Para>
            <Section2 ID="Sec6" OutputMedium="Online">
              <Heading>Production of MHC Class I:Peptide Tetrameric Complexes</Heading>
              <Para TextBreak="No">The strategy for generating class I MHC:peptide complexes was first described by Garboczi and Wiley in 1992 <CitationRef CitationID="CR7">(7)</CitationRef>. In this method, the β<Subscript>2</Subscript>-microglobulin (β<Subscript>2</Subscript>-m) and the MHC heavy chains are expressed separately in prokaryotic expression systems. These molecules are then purified from bacterial inclusion bodies and refolded in the presence of peptide. However, monomeric complexes bind TCR poorly, necessitating the formation into multimers to allow cooperative TCR binding. The method for combining MHC:peptide monomers into tetrameric complexes for staining antigen-specific T cells was devised by Altman and Davis in 1996 <CitationRef CitationID="CR5">(5)</CitationRef>. In this protocol, refolded monomers (which are fused to the Bir A substrate peptide) are biotinylated with the BirA enzyme and tetramerised with fluorochrome-conjugated streptavidin. Here, we shall provide an outline for this procedure, although it should be noted that customised tetramers are commercially available and may be purchased from outside sources.</Para>
              <Section3 ID="Sec7" OutputMedium="Online">
                <Heading>Expression of MHC Chains</Heading>
                <Para TextBreak="No">The most commonly used vectors to express MHC proteins are the pET plasmids (although other vectors may be used in their place). Genes inserted into the multiple cloning site of the pET plasmids are expressed as a T7 gene product, induced through the addition of IPTG.<OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Amplify the extracellular domains of the MHC class I heavy chains (α1, α2, and α3) or β<Subscript>2</Subscript>-m from a cDNA or/and existing plasmid and ligate into separate expression vectors. In the case of the MHC heavy chain, insert sequence immediately upstream of the BirA substrate peptide (BSP) sequence to produce MHC–BSP fusion product.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Transform plasmids into <Emphasis Type="Italic">E. coli</Emphasis> and incubate over night at 37°C with ampicillin selection (100 μg/ml). Pick single colonies, reselect with ampicillin and screen for the desired plasmid through enzyme digestion and sequence analysis.</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section3>
              <Section3 ID="Sec8" OutputMedium="Online">
                <Heading>Induction of MHC Protein</Heading>
                <Para TextBreak="No">
                  <OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Using a single colony containing either the heavy chain or β<Subscript>2</Subscript>-m expression vectors, inoculate 10 ml LB (+ampicillin selection) and grow overnight (37°C, shaking). Use 1 ml of this ‘starter’ broth to inoculate ‘bulk’ 200 ml LB (+ampicillin selection) and culture overnight (37°C, shaking).</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">The following day, add 50 ml of the bulk culture to each of four flasks containing 1 l LB (+ampicillin selection). Culture at 37°C with shaking, until the OD<Subscript>600</Subscript> reaches 0.6 (this takes ~3–4 h). Take a 1.5 ml sample to analyse pre-induction protein expression (see <Emphasis Type="Bold">Fig.</Emphasis>
                          <InternalRef RefID="Fig1_1_978-1-60327-527-9">
                            <Emphasis Type="Bold">1.1</Emphasis>
                          </InternalRef>).
<Figure Category="Standard" Float="Yes" ID="Fig1_1_978-1-60327-527-9">
                            <Caption Language="En">
                              <CaptionNumber>Fig. 1.1.</CaptionNumber>
                              <CaptionContent>
                                <SimplePara>Purification of MHC proteins.</SimplePara>
                                <SimplePara>Protein extracts from bacteria transformed with β<Subscript>2</Subscript>-m expression vectors taken prior to IPTG induction (pre-induction), 4 h after IPTG addition (post-induction) and following urea purification were resolved on a 15% SDS-PAGE gel and stained with Coomassie blue. Note the induction and purification of the β<Subscript>2</Subscript>-m sized band.</SimplePara>
                              </CaptionContent>
                            </Caption>
                            <MediaObject>
                              <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-527-9_1_Fig1_HTML.jpg" Format="JPEG" Rendition="HTML" Type="Linedraw"/>
                            </MediaObject>
                          </Figure>
                        </Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>3.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Induce the expression of MHC proteins by adding IPTG (final concentration 0.5 mM) and incubate for 4 h (37°C, shaking) to allow MHC protein expression.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>4.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Take a 1.5 ml post-induction sample for gel analysis (see <Emphasis Type="Bold">Fig.</Emphasis>
                          <InternalRef RefID="Fig1_1_978-1-60327-527-9">
                            <Emphasis Type="Bold">1.1</Emphasis>
                          </InternalRef>), measuring the OD<Subscript>600</Subscript> to equilibrate total pre- and post-induction bacterial concentration.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>5.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Pellet the remaining culture (20 min, 5000 <Emphasis Type="Italic">g</Emphasis>, 4°C). Decant supernatant and resuspend in ice-cold PBS (~10 ml per flask). Here, bacteria may be frozen at –80°C and stored overnight before inclusion body purification, or purified directly.</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section3>
              <Section3 ID="Sec9" OutputMedium="Online">
                <Heading>Inclusion Body Isolation</Heading>
                <Para TextBreak="No">
                  <OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">If frozen, thaw pellet on ice. Lyse bacteria by sonicating in bursts of 30 s, keeping on ice between bursts to prevent overheating. Repeat until suspension reaches milk-like consistency (this normally requires ~4 rounds of sonication).</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Transfer suspension to centrifuge tubes and spin for 10 min (13,000 <Emphasis Type="Italic">g</Emphasis>, 4°C). Both inclusion bodies (which should appear white) and cell debris (which appear as darkish matter) should pellet. If the supernatant remains cloudy re-spin.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>3.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">To remove cell debris, resuspend cell pellet in 25 ml of cold triton wash buffer. Spin for 10 min (13,000 <Emphasis Type="Italic">g</Emphasis>, 4°C) and discard supernatant. Wash another 2–3 times in triton buffer or until the supernatant has become clear (indicating that bacterial debris has been removed).</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>4.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">To remove detergent from inclusion body sample, resuspend the pellet in 25 ml of cold re-suspension buffer and pellet (10 min, 13,000 <Emphasis Type="Italic">g</Emphasis>, 4°C).</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>5.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Dissolve inclusion bodies by resuspending in a total volume of 25 ml fresh urea solution, mixing with a glass homogeniser. Rotate overnight at 4°C.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>6.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Spin urea extracts for 10 min (13,000 <Emphasis Type="Italic">g</Emphasis>, 4°C). Working on ice, pool supernatant and take a sample for gel analysis (see <Emphasis Type="Bold">Fig.</Emphasis>
                          <InternalRef RefID="Fig1_1_978-1-60327-527-9">
                            <Emphasis Type="Bold">1.1</Emphasis>
                          </InternalRef>).</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>7.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Determine protein concentration (using BCA analysis) and aliquot into 13 mg portions. Store at –80°C for up to 1 month before refolding.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>8.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">For gel analysis, pellet 1 ml of pre-induction and post-induction samples and resuspend in double-distilled water at a volume of 100 μl × OD<Subscript>600</Subscript> (equilibrating protein concentration). Run 10 μl of these resuspended samples alongside the urea-purified protein on a SDS gel (10% gel for MHC heavy chains and 15% for β<Subscript>2</Subscript>-m: see <Emphasis Type="Bold">Fig.</Emphasis>
                          <InternalRef RefID="Fig1_1_978-1-60327-527-9">
                            <Emphasis Type="Bold">1.1</Emphasis>
                          </InternalRef>).</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section3>
              <Section3 ID="Sec10" OutputMedium="Online">
                <Heading>Refolding and Purification of Class I MHC:Peptide Monomers</Heading>
                <Para TextBreak="No">The MHC heavy chain and β<Subscript>2</Subscript>-m proteins are mixed with the target peptide, refolding into monomeric MHC:peptide complexes. Monomers are then purified by chromatography.<OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Make up 1 l of refolding buffer and filter through a 0.45 μm membrane. Collect into a 2 l conical flask and cool to 4°C.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Dissolve 10 mg of peptide in 1 ml DMSO immediately before refolding.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>3.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Stir refolding buffer at 4°C and add dissolved peptide (final concentration ~10 μM), 26 mg β<Subscript>2</Subscript>-m protein (final concentration 2 μM) and 32 mg MHC heavy chain protein (final concentration 1 μM). Refold for 40 h at 4°C with stirring.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>4.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">To concentrate the refolded protein, filter the mix through a 0.45 μM membrane to remove precipitated proteins and load into an Amicon stir cell with a Diaflo PM10 150 mm membrane. Concentrate to 7 ml volume.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>5.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Refilter concentrate through a 0.45 μM membrane and purify the monomer using FPLC with Tris-buffered saline as the running buffer. Collect fractions of appropriate molecular weight and concentrate to below 3 ml using an Amicon stir cell (working at 4°C to limit protein degradation).</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section3>
              <Section3 ID="Sec11" OutputMedium="Online">
                <Heading>Biotinylation of Class I MHC:Peptide Monomers</Heading>
                <Para TextBreak="No">At this stage, monomeric class I MHC:peptides are biotinylated through the addition of the BirA enzyme. This enzyme biotinylates the BSP that is fused to the MHC heavy chain.<OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Transfer the purified monomers to a 50 ml Falcon tube and add<UnorderedList Mark="Dash">
                            <ItemContent>
                              <Para TextBreak="No">MgCl<Subscript>2</Subscript> (final concentration 5 mM)</Para>
                            </ItemContent>
                            <ItemContent>
                              <Para TextBreak="No">Leupeptin (final concentration 1 μM)</Para>
                            </ItemContent>
                            <ItemContent>
                              <Para TextBreak="No">Pepstatin (final concentration 1 μM)</Para>
                            </ItemContent>
                            <ItemContent>
                              <Para TextBreak="No">d-Biotin (final concentration 400 μM)</Para>
                            </ItemContent>
                            <ItemContent>
                              <Para TextBreak="No">ATP (dissolved in TBS: final concentration 5 mM)</Para>
                            </ItemContent>
                            <ItemContent>
                              <Para TextBreak="No">Bir A enzyme (final concentration 50 μM)</Para>
                            </ItemContent>
                          </UnorderedList>
                        </Para>
                        <Para TextBreak="No">Make up to a final volume of 4 ml with TBS, mix through inversion and incubate overnight at room temperature.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Filter the biotinylated complex through a 0.45 μm membrane and purify with FPLC (Tris-buffered saline running buffer). Collect fractions of appropriate molecular weight and immediately add leupeptin and pepstatin (final concentration of each at 1 μM) to prevent protein degradation.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>3.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Concentrate biotinylated complexes on an Amicon cell to a final volume of around 1 ml.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>4.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Determine protein concentration (i.e. with a BCA assay) and aliquot into 100 μg portions. Quick-freeze monomers in liquid nitrogen and store at –80°C until tetramerisation.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>5.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">See Notes for optional step (<Emphasis Type="Italic">see</Emphasis>
                          <Emphasis Type="Bold">Note 1</Emphasis>).</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section3>
              <Section3 ID="Sec12" OutputMedium="Online">
                <Heading>Tetramerisation of Class I MHC:Peptide Monomer</Heading>
                <Para TextBreak="No">Monomers are tetramerised through the addition of fluorochrome-conjugated streptavidin. To achieve maximal tetramerisation, streptavidin is initially added to an excess of monomer. Limiting avidin ensures that all biotin-binding sites are occupied with MHC monomers, promoting the formation of tetrameric complexes. The concentration of avidin is then progressively increased until all MHC has gone into tetramers and the avidin is saturating. Here, ExtrAvidin–Phycoerythrin (Sigma: E-4011) is used at a final concentration of 1 μl/μg of monomer (for instance, a total of 200 μl of avidin–PE to tetramerise 200 μg monomer).<OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Initially add half the total avidin–PE volume to monomer, mixing gently with a pipette tip. Incubate on ice for 30 min (keep in dark to protect fluorochrome).</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Divide the remaining avidin–PE into five equal volumes.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>3.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Add one aliquot of avidin–PE (equating to one tenth of total volume) to monomer. Mix and incubate for 20 min on ice (dark).</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>4.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Repeat step 3 another four times until the entire volume of avidin–PE has been added.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>5.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Test biotin availability following tetramerisation by ELISA. Plate out equivalent concentrations of monomer and tetramer in ELISA plates and perform twofold serial dilution (across eight wells). Perform standard ELISA, probing for biotin using streptavidin-peroxidase. Upon developing, the tetramer sample should appear to contain 1/8–1/16 as much biotin as the monomer. If biotin levels are in excess of this, repeat steps 3 and 4 until avidin has saturated biotin sites.</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section3>
            </Section2>
            <Section2 ID="Sec13" OutputMedium="Online">
              <Heading>Using Class I MHC:Peptide Tetrameric Complexes for Frequency Analysis of Antigen-Specific T Cells</Heading>
              <Para TextBreak="No">In this section, we shall describe the staining protocol for using class I MHC:peptide tetramers to identify antigen-specific T cells in whole lymphocyte populations.</Para>
              <Section3 ID="Sec14" OutputMedium="Online">
                <Heading>Staining Protocol for Class I MHC Tetramers</Heading>
                <Para TextBreak="No">
                  <OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Prepare single lymphocyte suspension from blood or organ tissues of test and control samples (<Emphasis Type="Italic">see</Emphasis>
                          <Emphasis Type="Bold">Note 2</Emphasis>).</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Lyse red blood cells and count live lymphocytes.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>3.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Transfer 1–2 ×10<Superscript>6</Superscript> live lymphocytes into staining vessels (usually 5 ml FACS tubes or 96-well plates). Pellet cells by centrifugation (5 min, 500 <Emphasis Type="Italic">g</Emphasis>) and wash twice with FACS buffer.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>4.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Stain cells first with tetramer by resuspending the cell pellet in 50 μl tetramer complex diluted to the optimal working concentration in FACS buffer (<Emphasis Type="Italic">see</Emphasis>
                          <Emphasis Type="Bold">Note 3</Emphasis>). Incubate for 30 min at 37°C in the dark (<Emphasis Type="Italic">see</Emphasis>
                          <Emphasis Type="Bold">Note 4</Emphasis>).</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>5.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Wash cells with FACS buffer and pellet (5 min, 500 <Emphasis Type="Italic">g</Emphasis>).</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>6.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Next stain for T-cell co-receptors. Resuspend cell pellet in a saturating concentration of antibodies (50 μl volume diluted in FACS buffer) against CD8 (for class II tetramers stain for CD4). In addition, antibodies directed against T-cell surface antigens may be included at this step (<Emphasis Type="Italic">see</Emphasis>
                          <Emphasis Type="Bold">Note 5</Emphasis>). Incubate for 30 min on ice in the dark.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>7.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Wash cells twice in FACS buffer and prepare for flow cytometric analysis. The sample may be analysed directly as live cells or fixed and stored for up to 2 days before analysis.<OrderedList>
                            <ListItem>
                              <ItemNumber>a</ItemNumber>
                              <ItemContent>
                                <Para TextBreak="No">For live analysis, resuspend cell pellet in 200 μl FACS buffer. Just prior to flow cytometry (between 1 and 30 min) add propidium iodide (final concentration at 2.5–5 μg/ml), to allow dead cell exclusion during analysis (<Emphasis Type="Italic">see</Emphasis>
                                  <Emphasis Type="Bold">Note 6</Emphasis>).</Para>
                              </ItemContent>
                            </ListItem>
                            <ListItem>
                              <ItemNumber>b</ItemNumber>
                              <ItemContent>
                                <Para TextBreak="No">For fixation, resuspend cell pellet in 100 μl of 1% formaldehyde and incubate for 20 min at room temperature (dark). Following fixation, wash cells twice in PBS. Resuspend in 200 μl PBS and store at 4°C in the dark until flow cytometry.</Para>
                              </ItemContent>
                            </ListItem>
                          </OrderedList>
                        </Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section3>
              <Section3 ID="Sec15" OutputMedium="Online">
                <Heading>Flow Cytometric Analysis of Tetramer Staining</Heading>
                <Para TextBreak="No">
                  <OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">For analysis, set up FSC versus SSC plot and set the primary gate (R1) upon lymphocyte-sized cells.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Where propidium iodide (PI) has been included set the secondary gate (R2) upon PI-negative lymphocytes. Combine gates (R1×R2) to restrict analysis to live lymphocytes (see <Emphasis Type="Bold">Fig.</Emphasis>
                          <InternalRef RefID="Fig1_2_978-1-60327-527-9">
                            <Emphasis Type="Bold">1.2</Emphasis>
                          </InternalRef>).
<Figure Category="Standard" Float="Yes" ID="Fig1_2_978-1-60327-527-9">
                            <Caption Language="En">
                              <CaptionNumber>Fig. 1.2.</CaptionNumber>
                              <CaptionContent>
                                <SimplePara>Quantitation of antigen-specific T cells by tetramer staining.</SimplePara>
                                <SimplePara>Blood from naïve C57BL/6 mice and mice infected 7 days earlier with herpes simplex virus (HSV) were stained with an APC-conjugated anti-CD8 antibody and the PE-conjugated tetramer of the dominant HSV peptide in complex with H2-K<Superscript>b</Superscript>. Frequency analysis was restricted to live lymphocytes (R1×R2) by gating upon lymphocyte-sized events (R1) that were PI negative (R2). <Emphasis Type="Italic">Inset</Emphasis> values show the percentage of CD8+ T cells that are tetramer positive for naïve and infected samples. Note that the HSV tetramer-specific population represents less than 0.1% of CD8+ T cells from naïve mice before expanding to around 9% of circulating CD8+ T cells after HSV infection.</SimplePara>
                              </CaptionContent>
                            </Caption>
                            <MediaObject>
                              <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-527-9_1_Fig2_HTML.jpg" Format="JPEG" Rendition="HTML" Type="Linedraw"/>
                            </MediaObject>
                          </Figure>
                        </Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>3.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">To analyse the frequency of antigen-specific T cells, show tetramer staining versus CD8 expression. Traditionally, the frequency of antigen-specific T cells is expressed as the percentage of T cells (CD4 or CD8) that stain positive with the MHC:peptide tetramer complex. Alternatively, when cells are from organ samples, the total number of antigen-specific T cells per organ may be a more appropriate value (see <Emphasis Type="Bold">Fig.</Emphasis>
                          <InternalRef RefID="Fig1_2_978-1-60327-527-9">
                            <Emphasis Type="Bold">1.2</Emphasis>
                          </InternalRef>).</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section3>
            </Section2>
            <Section2 ID="Sec16" OutputMedium="Online">
              <Heading>Analysis of Antigen-Specific T Cells Using Intracellular Cytokine Staining</Heading>
              <Para TextBreak="No">Upon recognition of their cognate antigen, T cells synthesise and secrete a range of cytokines, including IFN-γ, TNF-α, IL-2, IL-4 and IL-10. The ICS assay utilises this activity, identifying antigen-specific T cells through their production of cytokines in response to antigen. In this assay, the secretory pathway is blocked, causing the intracellular accumulation of nascent cytokines, which in turn are detected by antibody staining and flow cytometry <CitationRef CitationID="CR1">(1</CitationRef>–<CitationRef CitationID="CR4">4)</CitationRef>.</Para>
              <Para TextBreak="No">The primary advantage of the ICS versus tetramer staining is that precise knowledge of T-cell epitopes is not required. Specifically, the T-cell response against an entire pathogen may be enumerated following activation with stimulator cells that are infected with particular pathogen. However, peptide-specific responses are also routinely measured following stimulation with minimal peptides.</Para>
              <Section3 ID="Sec17" OutputMedium="Online">
                <Heading>Preparation of Virus-Infected Stimulator Cells</Heading>
                <Para TextBreak="No">To induce cytokine synthesis, responder T cells can be stimulated with either minimal peptides (stimulating peptide-specific T cells) or with virus-infected stimulator cells (stimulating virus-specific T cells). A number of cell types have been used as virus-infected stimulator cells, including fibroblasts <CitationRef CitationID="CR8">(8)</CitationRef> and dendritic cells <CitationRef CitationID="CR9">(9)</CitationRef>. Additionally, the lymphocyte sample may be directly infected <CitationRef CitationID="CR10">(10)</CitationRef>. The following section describes a generalised method for generating such infected stimulator cells.<OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Wash stimulator cells with serum-free media, aspirate supernatant and resuspend in a minimal volume of serum-free media containing the target virus at a multiplicity of infection (m.o.i) of between 1 and 5. Incubate cells for 60 min at 37°C.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Aspirate media and replace with an excess volume of growth media (e.g. RPMI with 10% FCS). Incubate cells for 4–16 h at 37°C to allow virus protein synthesis (<Emphasis Type="Italic">see</Emphasis>
                          <Emphasis Type="Bold">Note 7</Emphasis>).</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>3.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Following incubation, aspirate infectious supernatant, harvest cells and resuspend in T-cell media for use as virus-infected stimulators.</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section3>
              <Section3 ID="Sec18" OutputMedium="Online">
                <Heading>
                  <Emphasis Type="Italic">In Vitro</Emphasis> Stimulation of T Cells</Heading>
                <Para TextBreak="No">
                  <OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Prepare single lymphocyte cell suspensions from blood or organ tissue from test and control samples. Lyse red blood cells and wash in T-cell growth media (<Emphasis Type="Italic">see</Emphasis>
                          <Emphasis Type="Bold">Note 2</Emphasis>).</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Count live lymphocytes and transfer 1–2 ×10<Superscript>6</Superscript> live lymphocytes into wells of a 96-well round-bottom plate. In general, place each sample into four wells; duplicate wells with and without antigenic stimulation.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>3.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Stimulate T cells by adding either the cognate peptide (final concentration of between 0.1 and 1 μM) or virus-infected stimulator cells (between 1 and 2×10<Superscript>5</Superscript> cells per well) diluted in T-cell media. For unstimulated controls, add media alone or non-infected stimulator cells.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>4.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Immediately add Brefeldin A (<Emphasis Type="Italic">see</Emphasis>
                          <Emphasis Type="Bold">Note 8</Emphasis>) at a final concentration of between 5 and 10 μg/ml. Culture cells for 6 h at 37°C in 6.5% CO<Subscript>2</Subscript> to allow the intracellular accumulation of newly synthesised cytokines.</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section3>
              <Section3 ID="Sec19" OutputMedium="Online">
                <Heading>Staining and Analysis for ICS Assays</Heading>
                <Para TextBreak="No">
                  <OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Following in vitro stimulation, pellet cells (5 min, 500 <Emphasis Type="Italic">g</Emphasis>, 4°C) and wash twice in FACS buffer.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Resuspend the cell pellet in a saturating concentration of anti-CD8 and/or anti-CD4 antibodies and stain on ice for 30 min in the dark. In addition to T-cell co-receptors, it is useful to include antibodies directed against surface antigens that are constitutively expressed upon antigen-experienced T cells such as CD44 and CD11a/b (mouse) or CD45RA (human). Increasing the number of staining parameters enhances specificity and is particularly useful for rare populations.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>3.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Following surface staining, wash twice with FACS buffer to remove unbound antibody and pellet cells (5 min, 500 <Emphasis Type="Italic">g</Emphasis>, 4°C).</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>4.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Resuspend cell pellet in 100 μl of 1% formaldehyde and stand for 20 min at room temperature in the dark. Following fixation, wash cells twice with PBS.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>5.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Dilute antibodies against target cytokine(s) (e.g. IFN-γ, TNF-α, IL-2, IL-4 or IL-10) in 0.5% saponin. Pellet fixed cells (5 min, 500 <Emphasis Type="Italic">g</Emphasis>, 4°C) and resuspend in 50 μl of cytokine solution (separately stain stimulated cells with isotype control antibodies to validate cytokine specificity). Incubate cells at 4°C in the dark for at least 1 h (alternatively, cells may be left overnight in antibody suspension).</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>6.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Following incubation, wash cells twice in PBS (this may include 0.5% saponin if background levels are high). Resuspend cell pellet in 200 μl PBS for flow cytometry.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>7.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">For flow cytometric analysis, set the primary gate on lymphocyte-sized cells and analyse the expression of cytokines versus CD4 or CD8 (<Emphasis Type="Italic">see</Emphasis>
                          <Emphasis Type="Bold">Fig.</Emphasis>
                          <InternalRef RefID="Fig1_3_978-1-60327-527-9">
                            <Emphasis Type="Bold">1.3</Emphasis>
                          </InternalRef>).</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                  <Figure Category="Standard" Float="Yes" ID="Fig1_3_978-1-60327-527-9">
                    <Caption Language="En">
                      <CaptionNumber>Fig. 1.3.</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>Quantitation of virus and peptide-specific T cells by ICS.</SimplePara>
                        <SimplePara>Splenocytes from naïve C57BL/6 mice and mice infected 8 days earlier with HSV were stimulated with non-infected fibroblasts (cells alone), HSV-infected fibroblasts (infected cells) or a single HSV peptide (RR peptide). After 6 h, cells were stained for CD8 and intracellular IFN-γ. Dot-plots are gated upon lymphocyte-sized events and show the percentage of CD8+ T cells that are IFN-γ+ (<Emphasis Type="Italic">inset</Emphasis> value). Note that less than 0.1% of splenic CD8+ T cells from naïve mice produce IFN-γ following stimulation with either HSV or peptide, while around 2 and 10% of CD8+ T cells from HSV-infected mice produce IFN-γ following peptide or HSV-infected cell stimulation, respectively.</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <MediaObject>
                      <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-527-9_1_Fig3_HTML.jpg" Format="JPEG" Rendition="HTML" Type="Linedraw"/>
                    </MediaObject>
                  </Figure>
                </Para>
              </Section3>
            </Section2>
          </Section1>
          <Section1 ID="Sec20" OutputMedium="Online">
            <Heading>Notes</Heading>
            <Para TextBreak="No">
              <OrderedList>
                <ListItem>
                  <ItemNumber>1.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">It may be worthwhile to confirm that the monomer has been successfully biotinylated before commencing tetramerisation. Biotinylation may be confirmed simply through the use of a commercial biotin-ELISA detection kit. However, the sample may appear biotin-positive when only a small fraction of total monomers are actually biotinylated. In this case it is possible to purify biotinylated proteins through MonoQ-ion exchange. In MonoQ-ion exchange, biotinylated monomers run slightly heavier, allowing their separation from lighter/non-biotinylated monomers.</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>2.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">To validate the specificity of tetramer and ICS for antigen-specific T cells, it important to assess the background levels of staining against non-specific T cells. To do this, each experiment should include negative control samples that are known to have very few T cells of the defined specificity (&lt;0.1% of total T cells). Suitable controls include individuals that have not been challenged with the vaccine/infection (i.e. ‘naïve’ controls) or individuals of a distinct MHC haplotype.</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>3.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">For each new tetramer reagent (either produced in house or made commercially) it is important to confirm the ability to stain antigen-specific T cells and secondly to determine the appropriate working concentration for use. Here, we screen tetramers against CTL lines or expanded T-cell clones that are known to be specific for the MHC:peptide complex in question (this is confirmed by <Superscript>51</Superscript>CR release CTL assays or ICS assays). To determine an appropriate working concentration, make twofold serial dilutions of tetramer ranging from 1:50 to 1:1600 and use each to stain 1×10<Superscript>6</Superscript> antigen-specific T cells, followed by staining with anti-CD8 antibodies. Select the working concentration as the most dilute concentration that gives maximal MFI for labelled antigen-specific T cells.</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>4.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">In general, most groups report staining with tetramers at 37°C, as this appears to enhance the specificity of the tetramer–TCR interaction <CitationRef CitationID="CR11">(11)</CitationRef>. However, some variations in incubation temperature have been reported. Consequently, it may be worthwhile to initially compare tetramer staining efficiency at 4°C, room temperature and 37°C to determine optimal incubation temperatures for each individual tetramer.</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>5.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">A major benefit for using tetramers to identify antigen-specific T cells is the ability to phenotype these cells directly ex vivo. This can be achieved simply through co-staining samples with antibodies against T-cell-surface antigens, measuring the expression of these molecules on tetramer-positive T cells. Common T-cell-surface antigens that provide information on the activation state of the cell for mouse and/or human include CD69, CD25, CD44, CD62L, CD43, CD27, CD28, CD45RA/RO, CCR7, Ly6C, CD11a, α4β7, CLA, P and E-selectin ligands, in addition to a growing list of chemokine receptors.</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>6.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">PI is a red fluorescent dye that binds DNA through intercalating between nucleotides. PI is membrane impermeant, and therefore excluded from live cells but not from dead cells that have lost membrane integrity. PI is therefore commonly used to detect dead cells in a population during flow cytometry.</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>7.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">The information presented here provides only a general outline for infecting stimulator cells and is likely to require virus-specific modifications for optimal viral antigen presentation. A variable parameter in this procedure is the length of time for which infected cells are incubated before use in the ICS assay. In general, viruses that have regulated gene expression (i.e. herpes viruses) require a more prolonged incubation period than those with random gene expression (i.e. influenza), as early (β) and late (γ) proteins are expressed only after hours of infection. Secondly, where stimulation with infected cells remains poor, the level of antigen presentation may be enhanced through the pre-treatment of stimulator cells with IFN-γ. This cytokine is known to enhance surface MHC class I levels <CitationRef CitationID="CR12">(12)</CitationRef> and may be particularly important when working with viruses that impair MHC pathways <CitationRef CitationID="CR13">(13)</CitationRef>.</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>8.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">Brefeldin A is a metabolite of the fungus <Emphasis Type="Italic">Eupenicillium brefeldianum</Emphasis> that specifically blocks protein transport from the endoplasmic reticulum (ER) to the Golgi apparatus. Consequently, BFA treatment causes T cells that are actively synthesising cytokines to retain these molecules within the intracellular compartment. The expression of intracellular cytokines is then measured by antibody staining, identifying T cells that can respond to specific antigens (i.e. antigen-specific T cells).</Para>
                  </ItemContent>
                </ListItem>
              </OrderedList>
            </Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-527-9_Chapter_1.pdf" OutputMedium="All" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1">
              <CitationNumber>1.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T.</Initials>
                  <FamilyName>Jung</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>U.</Initials>
                  <FamilyName>Schauer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C.</Initials>
                  <FamilyName>Heusser</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C.</Initials>
                  <FamilyName>Neumann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C.</Initials>
                  <FamilyName>Rieger</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Detection of intracellular cytokines by flow cytometry</ArticleTitle>
                <JournalTitle>J Immunol Methods</JournalTitle>
                <VolumeID>159</VolumeID>
                <FirstPage>197</FirstPage>
                <LastPage>207</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3sXktVKlurY%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0022-1759(93)90158-4</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>8445253</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jung T, Schauer U, Heusser C, Neumann C, Rieger, C. Detection of intracellular cytokines by flow cytometry. J Immunol Methods 1993;159:197–207</BibUnstructured>
            </Citation>
            <Citation ID="CR2">
              <CitationNumber>2.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A.</Initials>
                  <FamilyName>Vikingsson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K.</Initials>
                  <FamilyName>Pederson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D.</Initials>
                  <FamilyName>Muller</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">Enumeration of IFN-gamma producing lymphocytes by flow cytometry and correlation with quantitative measurement of IFN-gamma</ArticleTitle>
                <JournalTitle>J Immunol Methods</JournalTitle>
                <VolumeID>173</VolumeID>
                <FirstPage>219</FirstPage>
                <LastPage>28</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXlsFGjsLc%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0022-1759(94)90300-X</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>7913946</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Vikingsson A, Pederson K, Muller D. Enumeration of IFN-gamma producing lymphocytes by flow cytometry and correlation with quantitative measurement of IFN-gamma. J Immunol Methods 1994;173:219–28.</BibUnstructured>
            </Citation>
            <Citation ID="CR3">
              <CitationNumber>3.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K.</Initials>
                  <FamilyName>Murali-Krishna</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JD.</Initials>
                  <FamilyName>Altman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M.</Initials>
                  <FamilyName>Suresh</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Counting antigen-specific CD8 T cells: a re-evaluation of bystander activation during viral infection</ArticleTitle>
                <JournalTitle>Immunity</JournalTitle>
                <VolumeID>8</VolumeID>
                <FirstPage>177</FirstPage>
                <LastPage>87</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXhsVChsr4%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S1074-7613(00)80470-7</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>9491999</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Murali-Krishna K, Altman JD, Suresh M, et al. Counting antigen-specific CD8 T cells: a re-evaluation of bystander activation during viral infection. Immunity 1998;8:177–87.</BibUnstructured>
            </Citation>
            <Citation ID="CR4">
              <CitationNumber>4.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KJ.</Initials>
                  <FamilyName>Flynn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GT.</Initials>
                  <FamilyName>Belz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JD.</Initials>
                  <FamilyName>Altman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R.</Initials>
                  <FamilyName>Ahmed</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DL.</Initials>
                  <FamilyName>Woodland</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PC.</Initials>
                  <FamilyName>Doherty</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Virus-specific CD8+ T cells in primary and secondary influenza pneumonia</ArticleTitle>
                <JournalTitle>Immunity</JournalTitle>
                <VolumeID>8</VolumeID>
                <FirstPage>683</FirstPage>
                <LastPage>91</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXktFOmsr8%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S1074-7613(00)80573-7</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>9655482</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Flynn KJ, Belz GT, Altman JD, Ahmed R, Woodland DL, Doherty PC. Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. Immunity 1998;8:683–91.</BibUnstructured>
            </Citation>
            <Citation ID="CR5">
              <CitationNumber>5.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JD.</Initials>
                  <FamilyName>Altman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PA.</Initials>
                  <FamilyName>Moss</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PJ.</Initials>
                  <FamilyName>Goulder</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Phenotypic analysis of antigen-specific T lymphocytes</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>274</VolumeID>
                <FirstPage>94</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XmtVyns7k%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1126/science.274.5284.94</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>8810254</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996;274:94–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR6">
              <CitationNumber>6.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P.</Initials>
                  <FamilyName>Klenerman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>V.</Initials>
                  <FamilyName>Cerundolo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PR.</Initials>
                  <FamilyName>Dunbar</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Tracking T cells with tetramers: new tales from new tools</ArticleTitle>
                <JournalTitle>Nat Rev Immunol</JournalTitle>
                <VolumeID>2</VolumeID>
                <FirstPage>263</FirstPage>
                <LastPage>72</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XjtFKht74%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nri777</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>12001997</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Klenerman P, Cerundolo V, Dunbar PR. Tracking T cells with tetramers: new tales from new tools. Nat Rev Immunol 2002;2:263–72.</BibUnstructured>
            </Citation>
            <Citation ID="CR7">
              <CitationNumber>7.</CitationNumber>
              <BibUnstructured>Garboczi DN, Hung DT, Wiley DC. HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. Proc Natl Acad Sci U S A 1992;89:3429–33. doi:<ExternalRef><RefSource>10.1073/pnas.89.8.3429</RefSource><RefTarget Address="10.1073/pnas.89.8.3429" TargetType="DOI"/></ExternalRef>.</BibUnstructured>
            </Citation>
            <Citation ID="CR8">
              <CitationNumber>8.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AT.</Initials>
                  <FamilyName>Stock</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM.</Initials>
                  <FamilyName>Jones</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WR.</Initials>
                  <FamilyName>Heath</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FR.</Initials>
                  <FamilyName>Carbone</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">CTL response compensation for the loss of an immunodominant class I-restricted HSV-1 determinant</ArticleTitle>
                <JournalTitle>Immunol Cell Biol</JournalTitle>
                <VolumeID>84</VolumeID>
                <FirstPage>543</FirstPage>
                <LastPage>50</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXjvFOmtQ%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1111/j.1440-1711.2006.01469.x</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>16956387</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Stock AT, Jones CM, Heath WR, Carbone FR. CTL response compensation for the loss of an immunodominant class I-restricted HSV-1 determinant. Immunol Cell Biol 2006;84:543–50.</BibUnstructured>
            </Citation>
            <Citation ID="CR9">
              <CitationNumber>9.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DC.</Initials>
                  <FamilyName>Tscharke</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WP.</Initials>
                  <FamilyName>Woo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IG.</Initials>
                  <FamilyName>Sakala</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Poxvirus CD8+ T-cell determinants and cross-reactivity in BALB/c mice</ArticleTitle>
                <JournalTitle>J Virol</JournalTitle>
                <VolumeID>80</VolumeID>
                <FirstPage>6318</FirstPage>
                <LastPage>23</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XntFWju7g%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1128/JVI.00427-06</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>16775319</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tscharke DC, Woo WP, Sakala IG, et al. Poxvirus CD8+ T-cell determinants and cross-reactivity in BALB/c mice. J Virol 2006;80:6318–23.</BibUnstructured>
            </Citation>
            <Citation ID="CR10">
              <CitationNumber>10.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E.</Initials>
                  <FamilyName>Hammarlund</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MW.</Initials>
                  <FamilyName>Lewis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SG.</Initials>
                  <FamilyName>Hansen</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Duration of antiviral immunity after smallpox vaccination</ArticleTitle>
                <JournalTitle>Nat Med</JournalTitle>
                <VolumeID>9</VolumeID>
                <FirstPage>1131</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXmvVWnsrk%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nm917</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>12925846</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hammarlund E, Lewis MW, Hansen SG, et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003;9:1131–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR11">
              <CitationNumber>11.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JA.</Initials>
                  <FamilyName>Whelan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PR.</Initials>
                  <FamilyName>Dunbar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DA.</Initials>
                  <FamilyName>Price</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent</ArticleTitle>
                <JournalTitle>J Immunol</JournalTitle>
                <VolumeID>163</VolumeID>
                <FirstPage>4342</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXmsleltrw%3D</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>10510374</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Whelan JA, Dunbar PR, Price DA, et al. Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent. J Immunol 1999;163:4342–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR12">
              <CitationNumber>12.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K.</Initials>
                  <FamilyName>Schwarz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M.</Initials>
                  <FamilyName>Broek</FamilyName>
                  <Particle>van Den</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S.</Initials>
                  <FamilyName>Kostka</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Overexpression of the proteasome subunits LMP2, LMP7, and MECL-1, but not PA28 alpha/beta, enhances the presentation of an immunodominant lymphocytic choriomeningitis virus T cell epitope</ArticleTitle>
                <JournalTitle>J Immunol</JournalTitle>
                <VolumeID>165</VolumeID>
                <FirstPage>768</FirstPage>
                <LastPage>78</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXkvFWisL0%3D</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>10878350</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schwarz K, van Den Broek M, Kostka S, et al. Overexpression of the proteasome subunits LMP2, LMP7, and MECL-1, but not PA28 alpha/beta, enhances the presentation of an immunodominant lymphocytic choriomeningitis virus T cell epitope. J Immunol 2000;165:768–78.</BibUnstructured>
            </Citation>
            <Citation ID="CR13">
              <CitationNumber>13.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DM.</Initials>
                  <FamilyName>Koelle</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HB.</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA.</Initials>
                  <FamilyName>Gavin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A.</Initials>
                  <FamilyName>Wald</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WW.</Initials>
                  <FamilyName>Kwok</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L.</Initials>
                  <FamilyName>Corey</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">CD8 CTL from genital herpes simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected cutaneous cells</ArticleTitle>
                <JournalTitle>J Immunol</JournalTitle>
                <VolumeID>166</VolumeID>
                <FirstPage>4049</FirstPage>
                <LastPage>58</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXitVGmsLw%3D</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>11238653</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.4049/jimmunol.166.6.4049</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Koelle DM, Chen HB, Gavin MA, Wald A, Kwok WW, Corey L. CD8 CTL from genital herpes simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected cutaneous cells. J Immunol 2001;166:4049–58.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Book>
  </Series>
</Publisher>
